Metipred (methylprednisolone) powder for solution for injections 250 mg. №1 vial


Manufacturer: Portugal



Primary and secondary insufficiency of the adrenal cortex (in this case, the first-line drugs are hydrocortisone or cortisone, if necessary, synthetic analogues can be used in combination with mineralocorticoids; simultaneous use of mineralocorticoids is especially important for the treatment of children). Congenital adrenal hyperplasia. Non-purulent thyroiditis. Hypercalcemia in cancer. Non-endocrine diseases. Rheumatic disease. As an additional therapy for short-term use (to remove the patient from an acute state or with an exacerbation of the process) for the following diseases: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (in some cases, low-dose maintenance therapy may be required); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tendosynovit; acute gouty arthritis; post-traumatic osteoarthritis; synovitis in osteoarthritis; epicondylitis. Collagenosises. In the period of exacerbation or in some cases as a maintenance therapy for the following diseases: systemic lupus erythematosus; systemic dermatomyositis (polymyositis); acute rheumatic heart disease; rheumatic polymyalgia in giant cell arteritis. Skin disease. Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative dermatitis; fungal mycosis; severe psoriasis; severe seborrheic dermatitis. Allergic condition. For the treatment of the following severe and allergic conditions if standard treatment is ineffective: seasonal or year-round allergic rhinitis; serum sickness; bronchial asthma; drug Allergy; contact dermatitis; atopic dermatitis. Eye disease. Severe acute and chronic allergic and inflammatory processes with eye damage, such as: allergic marginal corneal ulcers; eye damage caused by Herpes zoster; inflammation of the anterior segment of the eye; diffuse posterior uveitis and choroiditis; sympathetic ophthalmia; allergic conjunctivitis; keratitis; chorioretinitis; optic neuritis; iritis and iridocyclitis. Diseases of the respiratory system. Symptomatic sarcoidosis; Leffler syndrome, which cannot be treated with other methods; berylliosis; fulminant or disseminated pulmonary tuberculosis (used in combination with appropriate anti-TB chemotherapy); aspiration pneumonitis. Hematological diseases. Idiopathic thrombocytopenic purpura in adults; secondary thrombocytopenia in adults; acquired (autoimmune) hemolytic anemia; erythroblastopenia (erythrocytic anemia); congenital (erythroid) hypoplastic anemia. Oncological disease. How is palliative therapy used for such diseases: leukemia and lymphoma in adults; acute leukemia in children. Edema syndrome. For induction of diuresis or elimination of proteinuria in nephrotic syndrome, without uremia, of the idiopathic type or due to systemic lupus erythematosus. Diseases of the digestive tract. For removing the patient from a critical state in such diseases: ulcerative colitis; regional enteritis (Crohn’s disease). Nervous system disease. Multiple sclerosis in the acute phase; brain edema caused by a brain tumor. Diseases of other organs and systems. Tuberculosis meningitis with subarachnoid block or with the threat of block development, in combination with appropriate anti-TB chemotherapy; trichinosis with damage to the nervous system or myocardium. Organ transplantation. Contraindications Tuberculosis and other acute or chronic bacterial or viral infections with insufficient antibiotic and chemotherapy, systemic fungal infections. Hypersensitivity to methylprednisolone or to excipients. Administration of live or live attenuated Vacciness is contraindicated in patients who receive immunosuppressive doses of corticosteroids.